You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

CVP+R

Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma

You might also be interested in